Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study
Background Concurrent chemoradiotherapy (CCRT) is an optimal recommended treatment for stage III non‐small cell lung cancer (NSCLC). Herein, we aimed to investigate the efficacy and safety of oral vinorelbine plus cisplatin with concomitant radiotherapy for stage III NSCLC. Methods This prospective,...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13125 |
id |
doaj-57f2e00884e84169a55ca8946a81d21d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ping‐Chih Hsu John Wen‐Chang Chang Chun‐Chieh Wang Chen‐Te Wu Yu‐Ching Lin Chih‐Liang Wang Tin‐Yu Lin Shih‐Hong Li Yi‐Chen Wu Scott Chih‐Hsi Kuo Cheng‐Ta Yang Chien‐Ying Liu Chih‐Hung Chen |
spellingShingle |
Ping‐Chih Hsu John Wen‐Chang Chang Chun‐Chieh Wang Chen‐Te Wu Yu‐Ching Lin Chih‐Liang Wang Tin‐Yu Lin Shih‐Hong Li Yi‐Chen Wu Scott Chih‐Hsi Kuo Cheng‐Ta Yang Chien‐Ying Liu Chih‐Hung Chen Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study Thoracic Cancer Cisplatin concurrent chemoradiotherapy oral vinorelbine stage III non‐small cell lung cancer survival |
author_facet |
Ping‐Chih Hsu John Wen‐Chang Chang Chun‐Chieh Wang Chen‐Te Wu Yu‐Ching Lin Chih‐Liang Wang Tin‐Yu Lin Shih‐Hong Li Yi‐Chen Wu Scott Chih‐Hsi Kuo Cheng‐Ta Yang Chien‐Ying Liu Chih‐Hung Chen |
author_sort |
Ping‐Chih Hsu |
title |
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study |
title_short |
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study |
title_full |
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study |
title_fullStr |
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study |
title_full_unstemmed |
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study |
title_sort |
oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage iii non‐small cell lung cancer: results of a single‐arm prospective cohort study |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2019-08-01 |
description |
Background Concurrent chemoradiotherapy (CCRT) is an optimal recommended treatment for stage III non‐small cell lung cancer (NSCLC). Herein, we aimed to investigate the efficacy and safety of oral vinorelbine plus cisplatin with concomitant radiotherapy for stage III NSCLC. Methods This prospective, open‐label, single‐arm, observational cohort study was performed between January 2010 and September 2016. Patients were treated with two cycles of chemotherapy with 60 mg/m2 intravenous cisplatin on day 1 and 50 mg/m2 oral vinorelbine on days 1, 8, and 15; radiotherapy was administered concurrently from day 1 when chemotherapy was initiated. A total dose of 66–70 Gy radiotherapy was delivered in daily fractions of 2 Gy for 6.5–7 consecutive weeks. The tumor response was assessed after completing concomitant treatment. Results A total of 58 patients were enrolled and analyzed; 31 patients had stage IIIA NSCLC and 27 had stage IIIB NSCLC. After induction CCRT, 31 patients achieved an objective response (complete response in one and partial response in 30; the response rate was 53.4%). The median progression‐free survival was 6.73 months (95% confidence interval [CI], 5.42–7.91), duration of response was 12.30 months (95% CI, 5.59–19.01), and overall survival was 24.83 months (95% CI, 19.26–30.21). No treatment‐related mortality was observed, and neutropenia was the most common grade 3 and 4 treatment‐related toxicity (11 patients; 18.9%). Conclusions CCRT with the weekly regimen of oral vinorelbine plus triweekly cisplatin was effective and safe for stage III NSCLC. |
topic |
Cisplatin concurrent chemoradiotherapy oral vinorelbine stage III non‐small cell lung cancer survival |
url |
https://doi.org/10.1111/1759-7714.13125 |
work_keys_str_mv |
AT pingchihhsu oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT johnwenchangchang oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT chunchiehwang oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT chentewu oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT yuchinglin oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT chihliangwang oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT tinyulin oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT shihhongli oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT yichenwu oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT scottchihhsikuo oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT chengtayang oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT chienyingliu oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy AT chihhungchen oralvinorelbinepluscisplatinwithconcomitantradiotherapyasinductiontherapyforstageiiinonsmallcelllungcancerresultsofasinglearmprospectivecohortstudy |
_version_ |
1725868665829588992 |
spelling |
doaj-57f2e00884e84169a55ca8946a81d21d2020-11-24T21:54:08ZengWileyThoracic Cancer1759-77061759-77142019-08-011081683169110.1111/1759-7714.13125Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort studyPing‐Chih Hsu0John Wen‐Chang Chang1Chun‐Chieh Wang2Chen‐Te Wu3Yu‐Ching Lin4Chih‐Liang Wang5Tin‐Yu Lin6Shih‐Hong Li7Yi‐Chen Wu8Scott Chih‐Hsi Kuo9Cheng‐Ta Yang10Chien‐Ying Liu11Chih‐Hung Chen12Division of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDepartment of Oncology Chang Gung Memorial Hospital Linkou branch Taoyuan City TaiwanDivision of Radiation Oncology Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDepartment of Radiology Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Oncology, Department of Respiratory and Critical Care Medicine Chang Gung Memorial Hospital, Chiayi Branch Chiayi county TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic and Cardiovascular Surgery, Department of Surgery Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanDivision of Thoracic Medicine, Department of Internal Medicine Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine Taoyuan City TaiwanBackground Concurrent chemoradiotherapy (CCRT) is an optimal recommended treatment for stage III non‐small cell lung cancer (NSCLC). Herein, we aimed to investigate the efficacy and safety of oral vinorelbine plus cisplatin with concomitant radiotherapy for stage III NSCLC. Methods This prospective, open‐label, single‐arm, observational cohort study was performed between January 2010 and September 2016. Patients were treated with two cycles of chemotherapy with 60 mg/m2 intravenous cisplatin on day 1 and 50 mg/m2 oral vinorelbine on days 1, 8, and 15; radiotherapy was administered concurrently from day 1 when chemotherapy was initiated. A total dose of 66–70 Gy radiotherapy was delivered in daily fractions of 2 Gy for 6.5–7 consecutive weeks. The tumor response was assessed after completing concomitant treatment. Results A total of 58 patients were enrolled and analyzed; 31 patients had stage IIIA NSCLC and 27 had stage IIIB NSCLC. After induction CCRT, 31 patients achieved an objective response (complete response in one and partial response in 30; the response rate was 53.4%). The median progression‐free survival was 6.73 months (95% confidence interval [CI], 5.42–7.91), duration of response was 12.30 months (95% CI, 5.59–19.01), and overall survival was 24.83 months (95% CI, 19.26–30.21). No treatment‐related mortality was observed, and neutropenia was the most common grade 3 and 4 treatment‐related toxicity (11 patients; 18.9%). Conclusions CCRT with the weekly regimen of oral vinorelbine plus triweekly cisplatin was effective and safe for stage III NSCLC.https://doi.org/10.1111/1759-7714.13125Cisplatinconcurrent chemoradiotherapyoral vinorelbinestage III non‐small cell lung cancersurvival |